Market Overview

AbbVie Declares Inaugural Dividend of $0.40/Share

Share:
Related ABBV
AbbVie Initiates Pivotal Phase 3 Study of Veliparib for Patients with Early-Stage Triple-Negative Breast Cancer
Enanta Pharmaceuticals Announces Additional Data from AbbVie's M13-393 Study to be Presented at Liver Meeting
Is Now The Time To Pounce On The Pot Business? (Seeking Alpha)

The board of directors of AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical company, today declared the Company's first quarterly cash dividend of $0.40 per share. 

The cash dividend is payable Feb. 15, 2013 to stockholders of record at the close of business on Jan. 15, 2013.

AbbVie began trading on the New York Stock Exchange (NYSE) on Jan. 2, 2013 under the symbol "ABBV" and was also added to the S&P 500 Index.

About AbbVie

AbbVie (NYSE: ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.

AbbVie aims to help patients live healthier lives and collaborate on sustainable healthcare solutions. In 2013, AbbVie will employ approximately 21,000 people worldwide and market medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers

See full press release

Posted-In: News Guidance Management

 

Related Articles (ABBV)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→